While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Vikki Velasquez is a researcher and writer who has managed, coordinated, and directed various community and nonprofit organizations. She has conducted in-depth research on social and economic issues ...

Have you ever heard of the Fibonacci sequence? Or the Golden Ratio? Or the Golden Spiral? These mysterious numbers and shapes are all connected to each other. If you look closely, they can be found in ...

Richard Lee is a specialist in foreign exchange markets, contributing to a number of online platforms, including Yahoo Finance and DailyReckoning. Gordon Scott has been an active investor and ...

A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. View (RXRX) real-time stock price, chart, news, analysis, analyst reviews and more.